FAP-2286 is under clinical development by Clovis Oncology and currently in Phase II for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FAP-2286’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FAP-2286 overview

3B-201 is under development for the treatment of solid tumors including colorectal cancer, pancreatic ductal adenocarcinoma, adenoid cystic carcinoma, gallbladder cancer, head and neck cancer squamous cell carcinoma, neuroblastoma, soft tissue sarcoma. The drug candidate comprises of PurAffin ligands which are chemically stabilized peptide ligands (peptidomimetics) coupled to a therapeutic radioisotope via a linker and a chelator. The drug candidate is developed based on PurAffin technology. It acts by targeting Fibroblast Activation Protein Alpha (FAP). It is administered through intravenous route.

Clovis Oncology overview

Clovis Oncology (Clovis) is a biopharmaceutical company that develops and commercializes anti-cancer agents in the US and internationally. The company’s lead product includes Rubraca, an oral small molecule inhibitor of poly ADP-ribose polymerase used for the treatment of adults with BRCA mutation-associated metastatic castrate-resistant prostate cancer. Its major pipeline products include Rucaparib, which is intended for the treatment of ovarian cancer, prostate cancer, gastric cancer, and solid tumors with mutations in homologous recombination repair genes. The company’s preclinical candidate, FAP-2286 is a peptide-targeted radionuclide therapy and imaging agent intended for the treatment of cancer. It operates in California, the US; Cambridge, the UK; and Milan, Italy; among others. Clovis is headquartered in Boulder, Colorado, the US.

For a complete picture of FAP-2286’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.